Adalimumab for childhood onset uveitis

A V Ramanan^{1

2}, Catherine Guly²

Affiliations

Editorial

A V Ramanan et al. Ann Rheum Dis. 2018 Jul.

. 2018 Jul;77(7):961-962.

doi: 10.1136/annrheumdis-2017-212767. Epub 2018 Feb 28.

A V Ramanan^{1

2}, Catherine Guly²

No abstract available

Keywords: autoimmune diseases; juvenile idiopathic arthritis; tnf-alpha.

Conflict of interest statement

Competing interests: None declared.

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group. Ramanan AV, et al. N Engl J Med. 2017 Apr 27;376(17):1637-1646. doi: 10.1056/NEJMoa1614160. N Engl J Med. 2017. PMID: 28445659 Clinical Trial.
ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Quartier P, Baptiste A, Despert V, Allain-Launay E, Koné-Paut I, Belot A, Kodjikian L, Monnet D, Weber M, Elie C, Bodaghi B; ADJUVITE Study Group. Quartier P, et al. Ann Rheum Dis. 2018 Jul;77(7):1003-1011. doi: 10.1136/annrheumdis-2017-212089. Epub 2017 Dec 23. Ann Rheum Dis. 2018. PMID: 29275333 Clinical Trial.